| Item Type | Name |
|
Concept
|
Proteomics
|
|
Concept
|
Immunohistochemistry
|
|
Academic Article
|
Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
|
|
Academic Article
|
Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.
|
|
Academic Article
|
Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research.
|
|
Academic Article
|
The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis.
|
|
Academic Article
|
Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).
|
|
Academic Article
|
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
|
|
Academic Article
|
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
|
|
Academic Article
|
Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures.
|
|
Academic Article
|
Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.
|
|
Academic Article
|
Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors.
|
|
Academic Article
|
Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity.
|
|
Academic Article
|
Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
|
|
Academic Article
|
NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.
|
|
Academic Article
|
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
|
|
Academic Article
|
Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs.
|
|
Academic Article
|
History of retinoic acid receptors.
|
|
Academic Article
|
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.
|
|
Academic Article
|
Targeting autophagy in cancer management - strategies and developments.
|
|
Academic Article
|
Therapeutic options for management of endometrial hyperplasia.
|
|
Academic Article
|
Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules.
|
|
Academic Article
|
Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.
|
|
Academic Article
|
N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death.
|
|
Academic Article
|
Internal standard-based analysis of microarray data2--analysis of functional associations between HVE-genes.
|
|
Academic Article
|
Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms.
|
|
Academic Article
|
Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.
|
|
Academic Article
|
Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.
|
|
Academic Article
|
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
|
|
Academic Article
|
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
|
|
Academic Article
|
The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
|
|
Academic Article
|
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
|
|
Academic Article
|
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.
|
|
Academic Article
|
Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.
|
|
Academic Article
|
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
|
|
Academic Article
|
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
|
|
Academic Article
|
Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis.
|
|
Academic Article
|
Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers.
|
|
Academic Article
|
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.
|
|
Academic Article
|
Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study.
|
|
Academic Article
|
Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.
|
|
Grant
|
Mechanism of SHeA2 Action in Ovarian Cancer
|